Publications by authors named "S Choquet"
Primary central nervous system lymphoma of the spinal cord: A LOC network cohort study.
Rev Neurol (Paris)
December 2024
Purpose: Primary central nervous system lymphoma (PCNSL) mainly affects the brain (>90% cases); there are very little data pertaining to PCNSL involving the spinal cord.
Methods: We retrospectively selected from the French LOC network database adult immunocompetent patients diagnosed with PCNSL involving the spinal cord between 2011 and 2022.
Results: Of the 2043 patients records retrieved from the database, 16 patients (median age: 62.
Article Synopsis
- Vitreoretinal lymphoma (VRL) has a poor prognosis due to high relapse rates in the central nervous system, requiring treatments like high-dose chemotherapy with autologous stem cell transplantation (HCT-ASCT).
- A study analyzed 38 adult patients treated with HCT-ASCT for isolated VRL over 11 years, showing that 84% received a thiotepa-based regimen, with some patients experiencing serious side effects.
- Results revealed a significant relapse rate, particularly in the brain, but the strategy showed relatively good median survival rates: 96 months for progression-free survival and 92 months overall.
BACKGROUND Focal segmental glomerulosclerosis (FSGS) very rarely occurs in patients with multiple myeloma. Much more common are renal impairments secondary to monoclonal light-chain tubulopathy, AL amyloidosis, light-chain deposition disease, and the so-called monoclonal gammopathy of renal significance. CASE REPORT We report the case of a 79-year-old myeloma patient without noticeable medical problems but with a long history of myeloma treatment beginning 13 years ago.
View Article and Find Full Text PDFArticle Synopsis
- CAR T-cell therapy has shown promise as a treatment for central nervous system (CNS) lymphomas, despite previous concerns about neurotoxicity.
- Recent studies report high response rates in patients with CNS lymphomas, with complete response rates between 32% and 67%, and one-year progression-free survival (PFS) of 40% to 60%.
- Although neurotoxicity affects a significant percentage of patients (36% to 68%), the levels of severe neurotoxicity are relatively low (4.5% to 29%), indicating that CAR T-cell therapy could be a viable option for CNS lymphomas moving forward.
Tafasitamab plus lenalidomide (TAFA-LEN) treatment relevance pre- or post-anti-CD19 chimeric antigen receptor (CAR) T-cell therapy is debated. We analyzed patients with large B-cell lymphoma in the DESCAR-T registry treated with axi[1]cel or tisa-cel in ≥3rd line and TAFA-LEN before (n = 15, "TL-pre-CAR-T" set) or directly after (n = 52, "TL-post-CAR-T" set) CAR T-cell therapy. We compared TAFA-LEN v.
View Article and Find Full Text PDF